AveXis Inc (NASDAQ:AVXS) VP Andrew F. Knudten sold 2,000 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $118.13, for a total transaction of $236,260.00. Following the completion of the transaction, the vice president now directly owns 7,000 shares in the company, valued at $826,910. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
AveXis Inc (AVXS) traded down $1.93 during mid-day trading on Monday, hitting $114.10. 362,497 shares of the company traded hands, compared to its average volume of 736,933. AveXis Inc has a fifty-two week low of $53.94 and a fifty-two week high of $128.00. The firm has a market capitalization of $4,233.03, a P/E ratio of -20.45 and a beta of 2.10.
AveXis (NASDAQ:AVXS) last released its quarterly earnings results on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same quarter last year, the business posted ($0.87) EPS. analysts expect that AveXis Inc will post -6.23 EPS for the current year.
Several hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio acquired a new stake in AveXis during the third quarter worth about $116,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in AveXis by 57.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,241 shares of the company’s stock worth $137,000 after buying an additional 453 shares in the last quarter. Cubist Systematic Strategies LLC grew its stake in AveXis by 688.6% during the third quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after buying an additional 1,577 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in AveXis during the third quarter worth about $200,000. Finally, Deschutes Portfolio Strategy LLC acquired a new stake in AveXis during the third quarter worth about $203,000. Institutional investors and hedge funds own 81.42% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/02/05/avexis-inc-avxs-vp-sells-236260-00-in-stock.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.